Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Moodys
Medtronic
Dow
AstraZeneca

Last Updated: August 8, 2022

Investigational Drug Information for GDC-0623


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for GDC-0623?

GDC-0623 is an investigational drug.

There have been 184 clinical trials for GDC-0623. The most recent clinical trial was a Phase 3 trial, which was initiated on October 9th 2020.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are sixty-two US patents protecting this investigational drug and seven hundred and fifty-four international patents.

Recent Clinical Trials for GDC-0623
TitleSponsorPhase
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1
Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaNational Cancer Institute (NCI)Phase 1/Phase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLKazia Therapeutics LimitedPhase 2

See all GDC-0623 clinical trials

Clinical Trial Summary for GDC-0623

Top disease conditions for GDC-0623
Top clinical trial sponsors for GDC-0623

See all GDC-0623 clinical trials

US Patents for GDC-0623

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0623 See Plans and Pricing 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy Oncoceutics, Inc. (Philadelphia, PA) See Plans and Pricing
GDC-0623 See Plans and Pricing 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors Bayer Pharma Aktiengesellschaft (Berlin, DE) See Plans and Pricing
GDC-0623 See Plans and Pricing Benzimidazol-2-amines as MIDH1 inhibitors Bayer Pharma Aktiengesellschaft (Berlin, DE) See Plans and Pricing
GDC-0623 See Plans and Pricing Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) See Plans and Pricing
GDC-0623 See Plans and Pricing Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) See Plans and Pricing
GDC-0623 See Plans and Pricing Imipridones for gliomas Oncoceutics, Inc. (Philadelphia, PA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GDC-0623

Drugname Country Document Number Estimated Expiration Related US Patent
GDC-0623 Australia AU2014244117 2033-03-13 See Plans and Pricing
GDC-0623 Australia AU2014349150 2033-03-13 See Plans and Pricing
GDC-0623 Australia AU2019201896 2033-03-13 See Plans and Pricing
GDC-0623 Australia AU2020200875 2033-03-13 See Plans and Pricing
GDC-0623 Australia AU2020233606 2033-03-13 See Plans and Pricing
GDC-0623 Australia AU2022203043 2033-03-13 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Moodys
Medtronic
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.